Biosimilars Treatment Market By Product (Recombinant Non – Glycosylated Proteins, Recombinant Glycosylated Proteins, Recombinant Peptides), By Application (Oncology, Chronic And Autoimmune Disease, Blood Disorders, Growth Hormone Disease, Infectious Disease) - Growth, Future Prospects And Competitive Analysis 2017 - 2025

This report on the global biosimilars market studies the increasing demand for biosimilars as the number of biologic drugs used to treat chronic diseases is set to expire in the next 3-5 years, growing pressure to curtail healthcare expenditure, the cost-effectiveness of biosimilars, and strategic collaborations resulting in enhanced productivity and clinical trial activities for biosimilars.

For the purpose of this study, the biosimilars market is segmented into a product (recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides) and application type (oncology, chronic and autoimmune disorders, blood disorders, growth hormone disease, and infectious disease); market size estimates and forecasts for these segments for the period 2015 to 2025 are provided in terms of US$ Mn along with the respective CAGRs for the period 2017 to 2025, considering 2016 as the base year.

The pipeline analysis for the biosimilars market comprises projected market sales of Phase III drugs estimated till 2025. We have estimated sales of very specific molecules based on the type (SB4, HX575, ABP 980, and M834), sponsor, depicted peak sales by leading market experts, and other factors.

The geographic segmentation of the global biosimilars market is performed for the regions of North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. The regions are also further sub-segmented on the basis of major countries. Market size estimates and forecasts for these segments are provided in US$ Mn, along with the respective CAGRs for the period 2017-2025, using 2016 as the base year.

Based on product types, the global biosimilars market is categorized into:

  • Recombinant non-glycosylated proteins (insulin, filgrastim, somatropin)
  • Recombinant glycosylated proteins (monoclonal antibodies, erythropoietin)
  • Recombinant peptides (glucagon, calcitonin)

According to market experts, recombinant non-glycosylated proteins are expected to dominate the product segment due to the growing incidence of diabetes, the presence of several versions of insulin in the market, and the launch of cost-effective products.

The recombinant glycosylated proteins will record the fastest growth in the biosimilar product segment as the need for erythropoietin to counter blood-related disorders is increasing due to high-priced biologics and frequent application. Overall, the global biosimilars market is highly competitive, with multiple players like Pfizer, Inc., Biocon, F. Hoffman-La Roche AG, Amgen, Inc., etc., specializing in their respective fields. Consolidation activities are being increasingly witnessed on the competitive front with a view to increasing the technological advancement in the biosimilars market.

Based on application, the global biosimilars market is categorized into:

  • Oncology
  • Chronic and autoimmune diseases
  • Blood disorder
  • Growth hormone
  • Infectious disease

Oncology is expected to dominate the application segment due to rising incidences of cancer, the high cost of biologics, and the pressure to reduce healthcare expenditure. In the base year 2016, biosimilar applications for autoimmune disease and chronic disease showed great potential due to the changing off-patent scenario. Blood disease biosimilars are expected to grow significantly between 2017 and 2025, owing to the high cost of reference biologics and their widespread use.

The key factors assisting the biosimilar market's growth are the increasing prevalence of chronic disease, the aging population, the cost-effectiveness of biosimilars, and government initiatives to promote biosimilars, for example. The European Medicines Agency (EMA) has finalized the guidelines on biosimilars with their elements described in ICH (Q5E).

For the purpose of this study, the global biosimilars market is categorized into:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

In 2016, North America was identified as the largest market for biosimilars. According to the Centers for Disease Control and Prevention, in 2012, about half of adults, i.e., 117 million people, suffered from chronic disease, which can be considered a potential market for biosimilars.

According to the World Health Organization, over one-third of the European population above the age of 15 suffers from chronic disease. Europe is expected to be the second-largest market due to rising public awareness of the chronic disease and improved healthcare infrastructure. Newly approved biosimilar molecules have a good acceptance and penetration rate in the European market.

The growth of the Asia Pacific biosimilar market is attributed to factors like the rising prevalence of chronic diseases, increasing investments in R&D, and higher disposable income in these regions. However, factors such as the high prevalence of chronic disease, developing healthcare infrastructure, increasing awareness among people about healthcare, and an aging population are going to fuel the rapid growth of the biosimilars market in Latin America, the Middle East, and Africa in the near future.

Frequently Asked Question:

The market for Biosimilars Treatment Market is expected to reach USD$ 25.83 Bn in 2025.

The Biosimilars Treatment Market is expected to see significant CAGR growth over the coming years, at 23.1%.

The report is forecasted from 2017 -2025.

The base year of this report is 2016.

Pfizer, Inc., Biocon, F. Hoffman-La Roche AG, Amgen, Inc., etcme of the major players in the global market.

Choose License Type
Trusted By
Published Date:  Apr 2017
Category:  Pharmaceuticals
Report ID:   58422
Report Format:   PDF
Pages:   120
Rating:    4.7 (50)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
24/7 Research Support